Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein identified that may play central role in inflammatory bowel disease

11.11.2003


Researchers at the University of Virginia Health System have discovered that a protein expressed by the immune system, called TL1A, is linked to inflammatory bowel disease (IBD) in patients, especially Crohn’s disease. This is the first time TL1A has been linked to Crohn’s. In a study involving fifty patients at U.Va., published in the Nov. 1 issue of The Journal of Immunology, the research team found that TL1A was expressed in patients suffering from IBD, but not in control patients who are disease free. The finding could lead to new treatments for people who suffer from IBD, the general name for two diseases that cause inflammation in the intestines.



Ulcerative colitis causes inflammation and ulcers in the top layer of the intestinal lining, usually in the lower part of the large intestine, while in Crohn’s, the inflammation extends deep into the lining, usually in the small intestine. Over one million adults and children in the U.S. suffer from inflammatory bowel disease, with about 30,000 new cases diagnosed each year, according to the Crohn’s and Colitis Foundation of America. Adolescents and young adults are most susceptible to IBD and there is no cure.

"What we have discovered here at U.Va. is a cytokine, a key protein that regulates the immune response, that could be an important target for therapy in IBD patients who are not responding to current treatments for ulcerative colitis and Crohn’s disease," said Dr. Fabio Cominelli, principal investigator of the study, professor of internal medicine and microbiology and director of the Digestive Health Center of Excellence at U.Va. "Blocking the interaction between TL1A and its receptor in the immune response, called DR3, could be beneficial to the thousands of people suffering from chronic intestinal inflammation."


TL1A is a newly discovered member of the tumor necrosis factor (TNF) family of proteins thought to be expressed primarily in the endothelial cells that line the intestines. When TL1A interacts with DR3, found on active lymphocytes, the body can produce T cells as part of the inflammatory response associated with IBD. Anti-TNF drugs, such as Remicade®, are being used to treat people with moderate to severe Crohn’s symptoms that do not respond to conventional therapy.

Cominelli and his research team at U.Va. examined surgical specimens from patients with Crohn’s disease and ulcerative colitis, and from non-IBD control patients, who underwent therapeutic bowel resection. The researchers found minimal quantities of TL1A in the control specimens. But TL1A was present in the tissue of IBD patients and its expression correlated with the severity of inflammation. "The more inflammation present in a specimen, the more TL1A was found," Cominelli said.

The researchers concluded that TL1A expression is significantly associated with Crohn’s disease, where the protein was found in large numbers in macrophage and lymphocyte cells of the gut immune system. The study found that, in contrast, TL1A was primarily found in the plasma cells of ulcerative colitis patients, pointing to the different physiologies of the two diseases. Interestingly, TL1A expression was not found in the intestinal lining of Crohn’s or ulcerative colitis patients.

Cominelli and his team at U.Va. are continuing their research into TL1A and other proteins that may play a role in inflammatory bowel disease. Earlier this year, they found that the monoclonal antibody against tumor necrosis factor (TNF) in the drug Remicade® protects intestinal cells from programmed cell death and promotes healing in damaged IBD tissue.

Bob Beard | EurekAlert!
Further information:
http://hsc.virginia.edu/news
http://www.jimmunol.org/cgi/content/full/171/9/4868

More articles from Life Sciences:

nachricht Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden

nachricht The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>